Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Glaxo Wellcome UK Ltd., a prominent player in the pharmaceutical industry, is headquartered in Great Britain. Established in 1995 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has since made significant strides in research and development, focusing on innovative medicines and vaccines.
With a strong presence in Europe, North America, and emerging markets, Glaxo Wellcome is renowned for its core products, including treatments for respiratory diseases, HIV, and vaccines. Their commitment to scientific excellence and patient-centric solutions sets them apart in a competitive landscape.
As a leader in the global healthcare sector, Glaxo Wellcome UK Ltd. has achieved notable milestones, including advancements in biopharmaceuticals and a robust pipeline of new therapies, solidifying its position as a trusted name in health and wellness.
+58 vs industry average
Glaxo Wellcome UK Ltd.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has typical carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Glaxo Wellcome UK Ltd. yet.
Glaxo Wellcome UK Ltd., headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of GSK plc, which cascades its climate commitments and initiatives down to Glaxo Wellcome UK Ltd.
GSK plc has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its own operations (Scope 1 and 2) and by 2045 for its value chain (Scope 3). The company is also involved in various sustainability initiatives, such as the RE100, which aims for 100% renewable electricity, and the CDP, which focuses on transparency in environmental impact.
While specific reduction targets for Glaxo Wellcome UK Ltd. are not detailed, the overarching goals and strategies from GSK plc provide a framework for the subsidiary's climate commitments. As the company continues to align with these initiatives, it aims to contribute to a more sustainable future in the pharmaceutical industry.
No climate goals have been disclosed for Glaxo Wellcome UK Ltd. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Glaxo Wellcome UK Ltd. yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more